Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 26 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
PHARMALEC from Zaventem, company number BE0678956844, closed financial year 2025 with a result of € 92,828 after tax. For that financial year PHARMALEC recorded a gross margin of € 157,277 and equity of € 512,923. Compared with financial year 2024, the result moved from € 79,192 to € 92,828. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 30, 2026.
€ 512,923
▲ 22% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 92,828
▲ 17% vs 2024
Profit after tax over the fiscal year.
€ 1,458
▼ 91% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 506,723.
People and assets in 2025
€ 7,300
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 1.1 million
▼ 9% vs 2024
€ 110,147 is repaid this year. At this pace the long-term loan is gone in ≈ 10 years.
€ 3,732
▼ 94% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 21,800
▲ 51% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 123,836 | € 185,768 | € 141,907 | € 157,277 | ▲ 11% |
| Profit after taxes | € 69,856 | € 115,521 | € 79,192 | € 92,828 | ▲ 17% |
| Equity | € 225,381 | € 340,903 | € 420,094 | € 512,923 | ▲ 22% |
| Total debts | € 976,937 | € 912,305 | € 1,410,830 | € 1,292,974 | ▼ 8% |
| Cash | € 15,628 | € 12,471 | € 16,319 | € 1,458 | ▼ 91% |
| Land & buildings | € 294,394 | € 286,273 | € 111,261 | € 108,012 | ▼ 3% |
| Retained profit | € 217,321 | € 334,703 | € 413,894 | € 506,723 | ▲ 22% |
| Bank debt | € 862,674 | € 777,288 | € 1,169,874 | € 1,060,766 | ▼ 9% |
| Balance sheet total | € 1,202,318 | € 1,253,208 | € 1,830,925 | € 1,805,896 | ▼ 1% |
Key figures of PHARMALEC, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHARMALEC?
What happened at PHARMALEC in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 92,828 (▲ 17% vs 2024). Source: NBB ↗
- New establishment in Zaventem. KBO
- Start of the company according to the CBE. KBO
In short
From € 69,856 profit in 2022 to € 92,828 profit in 2025.
Paid € 144,659 in corporate taxes since 2022.
Best year ever: 2023, with € 115,521 profit.
Management
Behind PHARMALEC is Andreas GHIJSELINGS. Andreas GHIJSELINGS is also behind PHARMACAM and PHARMACIE MATTERNE APOTHEEK.
Directors
According to the 2025 annual accounts
Establishments
Establishment units
Physical locations of this company
Lenneke Marelaan 34 box 1
1932 Zaventem
Lenneke Marelaan 34
1932 Zaventem
Active since 1 October 2017
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0678.956.844
- VAT number
- BE 0678.956.844
- Registered office
- Lenneke Marelaan 34 bus 1, 1932 Zaventem
- Names & denominations
- PHARMALEC
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 28 July 2017
- Peppol
- Active · Active since 10 Jan 2025
- Activities · NACE
Verhuur en exploitatie van eigen of geleased residentieel onroerend goed, exclusief sociale woningen
Detailhandel in farmaceutische producten